Vaccines for the prevention of respiratory viral infections: problems and current status

Olszewska, Wieslawa; Helson, Rebecca; Openshaw, Peter

doi:10.1517/13543784.13.6.681

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutant viruses lacking either the G or both the G and SH genes also replicated in vivo in the respiratory tract of hamsters, although they were significantly restricted. However, both viruses were effective at eliciting hMPV-neutralizing serum antibodies [1062], suggesting that attenuated viruses of this type may be useful starting points for the development of a vaccine [1063].…”

Section: Human Metapneumovirusmentioning

confidence: 99%

Developments in Antiviral Drug Design, Discovery and Development in 2004

Meanwell

Belema²,

Carini³

et al. 2005

CDTID

View full text Add to dashboard Cite

This article summarizes key aspects of progress made during 2004 toward the design, discovery and development of antiviral agents for clinical use. Important developments in the identification, characterization and clinical utility of inhibitors of human immunodeficiency virus; the hepatitis viruses, hepatitis B, hepatitis C; the herpes family of viruses, herpes simplex viruses 1 and 2, varicella zoster virus, Epstein-Barr virus and human cytomegalovirus; the respiratory viruses, influenza, respiratory syncytial virus, human metapneumovirus, picornaviruses, measles and the severe acute respiratory syndrome coronavirus; human papilloma virus; rotavirus; Ebola virus and West Nile virus, are reviewed.

show abstract

Section: Human Metapneumovirusmentioning

confidence: 99%

Developments in Antiviral Drug Design, Discovery and Development in 2004

Meanwell

Belema²,

Carini³

et al. 2005

CDTID

View full text Add to dashboard Cite

show abstract

Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus

Schmitz¹,

Lou²,

Roberts³

et al. 2007

Comprehensive Medicinal Chemistry II

View full text Add to dashboard Cite

Live vaccines for human metapneumovirus designed by reverse genetics

Buchholz

Nagashima

Murphy

et al. 2006

Expert Review of Vaccines

View full text Add to dashboard Cite

Human metapneumovirus (HMPV) was first described in 2001 and has quickly become recognized as an important cause of respiratory tract disease worldwide, especially in the pediatric population. A vaccine against HMPV is required to prevent severe disease associated with infection in infancy. The primary strategy is to develop a live-attenuated virus for intranasal immunization, which is particularly well suited against a respiratory virus. Reverse genetics provides a means of developing highly characterized 'designer' attenuated vaccine candidates. To date, several promising vaccine candidates have been developed, each using a different mode of attenuation. One candidate involves deletion of the G glycoprotein, providing attenuation that is probably based on reduced efficiency of attachment. A second candidate involves deletion of the M2-2 protein, which participates in regulating RNA synthesis and whose deletion has the advantageous property of upregulating transcription and increasing antigen synthesis. A third candidate involves replacing the P protein gene of HMPV with its counterpart from the related avian metapneumovirus, thereby introducing attenuation owing to its chimeric nature and host range restriction. Another live vaccine strategy involves using an attenuated parainfluenza virus as a vector to express HMPV protective antigens, providing a bivalent pediatric vaccine. Additional modifications to provide improved vaccines will also be discussed.

show abstract

Vaccines for the prevention of respiratory viral infections: problems and current status

Cited by 3 publications

References 49 publications

Developments in Antiviral Drug Design, Discovery and Development in 2004

Developments in Antiviral Drug Design, Discovery and Development in 2004

Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus

Live vaccines for human metapneumovirus designed by reverse genetics

Contact Info

Product

Resources

About